A Phase I/Ib Open-Label, Multi-Center, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics and Preliminary Efficacy of Intravenous NBF 006 in Patients With Non-Small Cell Lung, Pancreatic, or Colorectal Cancer Followed by a Dose Expansion Study in Patients With KRAS-Mutated Non-Small Cell Lung Cancer
Latest Information Update: 29 Jul 2024
At a glance
- Drugs NBF 006 (Primary)
- Indications Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer
- Focus Adverse reactions; First in man
- Sponsors Nitto Biopharma
- 24 Jul 2024 Status changed from active, no longer recruiting to completed.
- 30 Aug 2023 Status changed from recruiting to active, no longer recruiting.
- 06 Jun 2023 Results (n=21) assessing the safety, tolerability, and PK of NBF-006 in patients with non-small cell lung, pancreatic, or colorectal cancer, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.